Chardan Capital Markets Starts Esperion Therapeutics (ESPR) at Sell
Tweet
Share
E-mailGet Alerts ESPR Hot Sheet
Price: $3.18 --0%
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Chardan Capital Markets initiated coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Sell rating and a price target of $55.00.
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $113.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Rio Tinto (RIO) at Underweight
- TD Cowen Assumes Maze Therapeutics (MAZE) at Buy
- Keefe, Bruyette & Woods Resumes Bank of Montreal (BMO:CN) (BMO) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Chardan Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
